Today, we welcome Dr. Antonio Luis Cuesta Muñoz, an endocrinologist and the scientific director of the International Institute of Genetics of Diabetes, in Spain. In this episode, we discuss Dr. Cuesta Muñoz's paper in Clinical Infectious Disease titled, "Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 Mortality".

Thanks for joining us for this wonderful opportunity to learn from one of the leading researchers on the COVID pandemic. Enjoy!

Talking Points:

• About this podcast and our mission (0:00)
• Dr. Cuesta Muñoz involvement  with the fight against COVID-19 (1:42)
• A summary of Dr. Cuesta Muñoz's literature on COVID-19 (2:58)
• The role of the renin-angiotensin system on COVID-19 (3:26)
• The pathogenesis of COVID-19 (4:42)
• The relationship between Ace-2 and angiotensin (5:26)
• Studies that support an increase in angiotensin 17 (6:10)
• The relationship between SGLT2 Inhibitors and COVID-10 (6:42)
• How does metabolic syndrome relate to COVID-19? (7:01)
• Dr. Cuesta Muñoz explains the side effects of SGLT2 inhibitors (8:57)
• Final thoughts (9:25)

Resources: "Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 Mortality" Clinical Infectious Disease. 2020 Apr 8. https://pubmed.ncbi.nlm.nih.gov/32266375/